SeekingAlpha · Aug 17, 2026
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2026 Earnings Call August 17, 2026 5:00 PM EDTCompany ParticipantsIlan Danieli - Founder, President, CEO & DirectorConference...
PR
NASDAQ · PRPO
Precipio, Inc.
Healthcare · Medical - Diagnostics & Research
$25.60
Up+$1.31 (+5.12%)
Updated Sep 11, 2026, 12:40 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.66M
- P/E ratio
- -31.99
- Dividend yield
- 0.00%
- 52-week range
- $16.00 – $33.63
- Volume
- 132.82K
- Avg. volume
- 15.04K
Price performance
PRPO price history
1M range · 0 trading sessions · Daily adjusted prices
PRPO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PRPO news
The latest Smart Investors Daily articles mentioning PRPO.
Stock researchCompany · Overview
PRPO research
Overview
Company profile and research snapshot.
Company profile
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 22, 2019 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Precipio Q2 EPS $(0.12) Down From $0.05 YoY, Sales $7.021M Up From $5.654M YoY
Precipio (NASDAQ:PRPO) reported quarterly losses of $(0.12) per share. This is a 340 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $7.021 million in sales this
Yahoo · Jul 31, 2026
Precipio Announces Q2-2026 Shareholder Update Call
Conference Call will be held on August 17th, 2026, at 5:00 PM EDTNEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. “We are excited to share our upcoming results for Q2. The team continues to mak
Benzinga · Mar 10, 2026
Precipio Announces Data On New Bloodhound Assay For Chronic Myeloid Leukemia Published In Journal Of Clinical Pathology
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
